Orphazyme Provides an Update on its New Drug Application to the FDA
Orphazyme A/S (NASDAQ: ORPH) provided an update on the process and anticipated timelines for resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration. Up Over 12% Shares of Orphazyme A/S (NASDAQ: ORPH) gained over 12%...